


# Clinical trials now enrolling.



Click NCT number to view clinical trial details on [clinicaltrials.gov](#).<sup>a</sup> Click BROCHURE to view clinical trial details.

## ADC

### Solid tumors TROPiCS-03

Phase 2 open-label study of sacituzumab govitecan in participants with metastatic solid tumors (NSCLC, HNSCC, SCLC, or endometrial cancer)

[NCT03964727](#) [BROCHURE](#)

### mUC TROPiCS-04

Phase 3 open-label study of sacituzumab govitecan versus treatment of physician's choice in participants with metastatic or locally advanced unresectable urothelial cancer

[NCT04527991](#) [BROCHURE](#)

### mUC TROPHY U-01

Phase 2 multicohort, open-label study of sacituzumab govitecan in participants with metastatic or locally advanced urothelial cancer

[NCT03547973](#) [BROCHURE](#)

### NSCLC EVOKE-01

Phase 3 randomized, open-label, multicenter study of sacituzumab govitecan versus docetaxel in participants with advanced or metastatic NSCLC with progression on or after platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy

[NCT05089734](#) [BROCHURE](#)

### NSCLC EVOKE-02<sup>b</sup>

Phase 2 open-label multicenter study of sacituzumab govitecan combinations in first line treatment of patients with advanced or metastatic NSCLC without actionable genomic alterations

[NCT05186974](#) [BROCHURE](#)

## CD47

### AML GS-US-546-5920

Phase 2 open-label, multicohort study of magrolimab combination therapy in participants with AML. Now enrolling Cohort 2 evaluating the safety and efficacy of magrolimab + MEC in participants with R/R AML

[NCT04778410](#) [BROCHURE](#)

### HNSCC ELEVATE: Head and Neck Cancer

Phase 2 open-label study of magrolimab combination therapy in patients with metastatic or unresectable, locally recurrent HNSCC

[NCT04854499](#) [BROCHURE](#)

### Solid tumors ELEVATE: Lung and Urothelial Cancer

Phase 2 open-label multi-arm study of magrolimab + docetaxel combination therapy in patients with previously treated solid tumors (mNSCLC, mUC, and mSCLC)

[NCT04827576](#) [BROCHURE](#)

### TNBC ELEVATE: TNBC

Phase 2 randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel in patients with mTNBC

[NCT04958785](#) [BROCHURE](#)

## CAR T

### MCL ZUMA-2

Phase 2/Cohort 3 study evaluating the efficacy of brexucabtagene autoleucel in participants with R/R MCL who have been treated with up to 5 prior regimens but have not received prior therapy with a BTKi

[NCT04880434](#) [BROCHURE](#)

### pALL, pNHL ZUMA-4

Phase 2 study evaluating the safety and efficacy of brexucabtagene autoleucel in pediatric and adolescent participants with R/R B-precursor ALL or R/R B-cell NHL

[NCT02625480](#) [BROCHURE](#)

### AML KT-US-486-0201

Phase 1 open-label, multicenter study evaluating the safety of KITE-222, an autologous anti-CLL-1 CAR T-cell therapy, in subjects with R/R AML

[NCT04789408](#) [BROCHURE](#)

### BCL KITE-363

Phase 1 open-label, multicenter study evaluating the safety and efficacy of KITE-363, an autologous anti-CD19/CD20 CAR T-cell therapy, in subjects with R/R BCL

[NCT04989803](#) [BROCHURE](#)

<sup>a</sup>Clinicaltrials.gov may not reflect the most up-to-date information on the trials shown.  
<sup>b</sup>In collaboration with Merck.

**ADC**, antibody-drug conjugate; **ALL**, acute lymphocytic leukemia; **AML**, acute myeloid leukemia; **BTKi**, Bruton's tyrosine kinase inhibitor; **BCL**, B-cell lymphoma; **CAR**, chimeric antigen receptor; **CD47**, cluster of differentiation 47; **CLL-1**, C-type lectin-like molecule-1; **HNSCC**, head and neck squamous cell carcinoma; **mNSCLC**, metastatic non-small cell lung cancer; **mSCLC**, metastatic small cell lung cancer; **mTNBC**, metastatic triple-negative breast cancer; **mUC**, metastatic urothelial cancer; **MCL**, mantle cell lymphoma; **MEC**, mitoxantrone, etoposide, cytarabine; **NHL**, non-Hodgkin lymphoma; **NCT**, national clinical trial; **NSCLC**, non-small cell lung cancer; **pALL**, pediatric acute lymphocytic leukemia; **pNHL**, pediatric non-Hodgkin lymphoma; **R/R**, relapsed/refractory; **SCLC**, small cell lung cancer; **T**, T-cell therapy; **TNBC**, triple-negative breast cancer.

Contact Kite Medical Information • Contact Gilead Medical Information

The safety and efficacy of these investigational agents and/or uses have not been established. There is no guarantee that they will become commercially available.

Gilead and Kite are separate entities with an integrated vision for the future of oncology. GILEAD and the GILEAD logo are trademarks of Gilead Sciences, Inc. KITE and the KITE logo are trademarks of Kite Pharma, Inc. All other trademarks referenced herein are the property of their respective owners. © 2022 Gilead Sciences, Inc. All rights reserved. US-UNBP-0706 03/22

Last updated February 23, 2022